BATS British American Tobacco p.l.c.
British American Tobacco p.l.c. provides tobacco and nicotine products to consumers in the United States, Europe, Latin America, Canada, the Asia-Pacific, the Middle East, Central Asia, Caucasus, and Africa. The company offers vapour products; heated products, which consists of a battery-powered device and a plant-based substance consumable that is heated; modern oral products, such as nicotine pouches; combustibles, including cigarette sticks and other tobacco stick products; traditional oral products, such as snus and moist snuff; and fine cut/roll-your-own tobacco products. It sells its products under the Vuse, glo, Velo, Grizzly, Kodiak, Dunhill, Kent, Lucky Strike, Pall Mall, Rothmans, Newport, Natural American Spirit, and Camel Snus brands, as well as Vogue, Viceroy, Kool, Peter Stuyvesant, Craven A, and State Express 555 brands. The company distributes its products to retail outlets. British American Tobacco p.l.c. was founded in 1902 and is headquartered in London, the United Kingdom.…
Industry Peers
TobaccoKey Statistics
About British American Tobacco (LON: BATS)
›
British American Tobacco (LON: BATS) is listed on the London Stock Exchange, where its shares trade in pence sterling (GBp). It belongs to the Tobacco industry, part of the Consumer Defensive sector, and reports about 47,797 employees.
The shares were at 4347.00 GBp on 19 November 2026, up 7.4% over 52 weeks.
At a market capitalisation of 93.35B GBP, it trades at 14.9 times trailing earnings and 11.2 times forward earnings. The median trailing P/E of its 7 largest Tobacco peers is 13.3, a premium of 13% for BATS. It pays a dividend yielding 5.50% (it pays out 83% of its earnings), against a median of 5.50% among the dividend payers in that peer group.
British American Tobacco reports return on equity of 16.2%, an operating margin of 34.7% and revenue up 1.4% year over year.
Its debt exceeds its cash by 32.53B GBP, a debt-to-equity ratio of 0.73. Its Piotroski F-score is 7 out of 9, a strong reading of its financial health. 14 analysts cover the stock, with an average rating of Buy; their mean price target of 5192.86 GBp is 19.5% above the current price. The next earnings report is expected on 10 February 2027.